EP0406857B1
(en)
*
|
1989-07-07 |
1995-05-24 |
Takeda Chemical Industries, Ltd. |
Proteins and production thereof
|
US5314995A
(en)
*
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
JP3260364B2
(ja)
*
|
1990-02-06 |
2002-02-25 |
武田薬品工業株式会社 |
免疫複合体
|
ZA912490B
(en)
*
|
1990-04-19 |
1992-12-30 |
Res Dev Foundation |
Antibody conjugates for treatment of neoplastic disease
|
US5349053A
(en)
*
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
US5594107A
(en)
*
|
1990-08-22 |
1997-01-14 |
University Of Saskatchewan |
Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
|
US5273889A
(en)
*
|
1990-08-22 |
1993-12-28 |
University Of Saskatchewan |
Gamma-iterferon-leukotoxin gene fusions and uses thereof
|
WO1992003569A1
(en)
*
|
1990-08-29 |
1992-03-05 |
Centre Hospitalier Regional De Nantes |
Protein polyligands joined to a stable protein core
|
US5650150A
(en)
*
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
CA2095836C
(en)
*
|
1990-11-09 |
1999-04-06 |
Stephen D. Gillies |
Cytokine immunoconjugates
|
EP0556328A4
(en)
*
|
1990-11-09 |
1994-06-08 |
Abbott Lab |
Bridging antibody fusion constructs
|
AU1643692A
(en)
*
|
1991-03-07 |
1992-10-06 |
Seragen, Inc. |
Use of cell surface receptor targeted molecules for the treatment of viral diseases
|
JP3105629B2
(ja)
*
|
1991-04-23 |
2000-11-06 |
サングスタット メディカル コーポレイション |
特異的結合ペアのメンバーの細胞活性調節接合体
|
US5326559A
(en)
*
|
1991-05-16 |
1994-07-05 |
Miller D Douglas |
Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
|
ATE168014T1
(de)
*
|
1991-11-08 |
1998-07-15 |
Somatogen Inc |
Hämoglobine als arzneimittelabgabesystem
|
GB9324807D0
(en)
*
|
1993-12-03 |
1994-01-19 |
Cancer Res Campaign Tech |
Tumour antibody
|
ATE207366T1
(de)
*
|
1993-12-24 |
2001-11-15 |
Merck Patent Gmbh |
Immunokonjugate
|
GB9415379D0
(en)
*
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
ES2167391T3
(es)
*
|
1994-09-16 |
2002-05-16 |
Merck Patent Gmbh |
Inmunoconjugados ii.
|
US7820798B2
(en)
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US6090382A
(en)
*
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US6482927B1
(en)
*
|
1995-11-27 |
2002-11-19 |
Millennium Pharmaceuticals, Inc. |
Chimeric proteins comprising the extracellular domain of murine Ob receptor
|
US6620413B1
(en)
|
1995-12-27 |
2003-09-16 |
Genentech, Inc. |
OB protein-polymer chimeras
|
US20050019325A1
(en)
|
1996-01-08 |
2005-01-27 |
Carter Paul J. |
WSX receptor agonist antibodies
|
US6541604B1
(en)
|
1996-01-08 |
2003-04-01 |
Genentech, Inc. |
Leptin receptor having a WSX motif
|
US7074397B1
(en)
|
1996-01-08 |
2006-07-11 |
Genentech, Inc. |
Method for enhancing proliferation or differentiation of a cell using ob protein
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
PL188192B1
(pl)
*
|
1996-02-09 |
2004-12-31 |
Abbott Lab Bermuda Ltd |
Izolowane ludzkie przeciwciało albo jego część wiążąca antygen, rekombinowane ludzkie przeciwciało albo jego część wiążąca antygen, kompozycje farmaceutyczne, izolowane kwasy nukleinowe, rekombinowany wektor ekspresyjny, komórka gospodarza, sposób syntetyzowania przeciwciała ludzkiego, które wiąże ludzki TNFalfa, sposób hamowania aktywności ludzkiego TNFalfa in vitro, przeciwciało albo jego częśćwiążąca antygen, zastosowanie przeciwciała albo jego części wiążącej antygen
|
WO1999029732A2
(en)
|
1997-12-08 |
1999-06-17 |
Lexigen Pharmaceuticals Corporation |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
DE69943022D1
(de)
|
1998-03-19 |
2011-01-20 |
Human Genome Sciences Rockville |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
JP2002537769A
(ja)
|
1999-02-26 |
2002-11-12 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトエンドカインαおよび使用方法
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
MXPA02001417A
(es)
|
1999-08-09 |
2002-08-12 |
Lexigen Pharm Corp |
Complejos multiples de citosina-anticuerpo.
|
US7091321B2
(en)
|
2000-02-11 |
2006-08-15 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
EP2281843B1
(en)
|
2000-06-16 |
2016-10-12 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to BLyS
|
EP1292334A4
(en)
*
|
2000-06-22 |
2003-11-19 |
Idec Pharma Corp |
BISPECIFIC FUSION PROTEIN AND METHOD FOR USE TO ENHANCE THE KILLING OF TARGET CELLS BY EFFECTOR CELLS
|
TWI327600B
(en)
|
2000-11-28 |
2010-07-21 |
Medimmune Llc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
AU2002250032B2
(en)
|
2001-02-09 |
2008-06-05 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor (CCR5) HDGNR10
|
ZA200305980B
(en)
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
HUP0303428A2
(hu)
|
2001-03-07 |
2004-01-28 |
Merck Patent Gmbh. |
Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
US7064189B2
(en)
|
2001-05-25 |
2006-06-20 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
EP1414471B1
(en)
|
2001-07-17 |
2012-06-13 |
Research Development Foundation |
Therapeutic agents comprising pro-apoptotic proteins
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
CN100390282C
(zh)
|
2001-12-04 |
2008-05-28 |
默克专利有限公司 |
具有调节的选择性的il-2融合蛋白
|
EP2270049A3
(en)
|
2002-04-12 |
2011-03-09 |
Medimmune, Inc. |
Recombinant anti-interleukin-9-antibody
|
GB0209896D0
(en)
*
|
2002-04-30 |
2002-06-05 |
Molmed Spa |
Conjugate
|
JP4643255B2
(ja)
|
2002-06-10 |
2011-03-02 |
バクシネックス インコーポレーティッド |
乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド
|
US7232888B2
(en)
|
2002-07-01 |
2007-06-19 |
Massachusetts Institute Of Technology |
Antibodies against tumor surface antigens
|
DK1572748T3
(da)
|
2002-12-17 |
2010-08-23 |
Merck Patent Gmbh |
Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
|
EP2248899B8
(en)
|
2003-03-19 |
2015-07-15 |
Biogen MA Inc. |
NOGO receptor binding protein
|
JP4838720B2
(ja)
|
2003-05-13 |
2011-12-14 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
転移および転移がもたらす骨格関連現象を調節する方法
|
ATE552850T1
(de)
|
2003-12-23 |
2012-04-15 |
Genentech Inc |
Neue anti-il 13-antikörper und verwendungen dafür
|
ATE393169T1
(de)
|
2003-12-30 |
2008-05-15 |
Merck Patent Gmbh |
Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
|
EA011859B9
(ru)
|
2004-01-05 |
2013-07-30 |
Емд Лексиген Ресерч Сентер Корп. |
Соединения для адресной доставки препарата к ткани или органу-мишени
|
US8486893B2
(en)
|
2004-06-24 |
2013-07-16 |
Biogen Idec Ma Inc. |
Treatment of conditions involving demyelination
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
AU2005259487A1
(en)
*
|
2004-06-30 |
2006-01-12 |
Novartis Ag |
Conjugates of antibody and duoarmycin derivatives as antitumor agents
|
EP2329714A1
(en)
|
2004-08-03 |
2011-06-08 |
Biogen Idec MA Inc. |
Influence of TAJ in the neuronal functions
|
US8165517B2
(en)
|
2005-01-19 |
2012-04-24 |
The Trustees Of The University Of Pennsylvania |
Methods for identifying inhibitors of vascular injury
|
JP2008546805A
(ja)
|
2005-06-23 |
2008-12-25 |
メディミューン,エルエルシー |
最適な凝集および断片化プロフィールを有する抗体製剤
|
US7482124B2
(en)
|
2005-07-08 |
2009-01-27 |
Bristol-Myers Squibb Company |
Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
|
EP1904104B1
(en)
|
2005-07-08 |
2013-09-11 |
Biogen Idec MA Inc. |
Sp35 antibodies and uses thereof
|
EP2510934A1
(en)
|
2005-11-04 |
2012-10-17 |
Biogen Idec MA Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
BRPI0619657A2
(pt)
|
2005-11-04 |
2011-11-08 |
Genentech Inc |
métodos de prevenção ou melhoria de doença ocular, uso de um inibidor de complemento, uso de um sirna especìfico para uma proteìna do sistema complemento e uso de um ácido nucleico que codifica um inibidor do sistema complemento
|
ZA200804082B
(en)
|
2005-11-07 |
2010-02-24 |
Scripps Research Inst |
Compositions and methods for controlling tissue factor signaling specificity
|
AU2006320479B2
(en)
|
2005-12-02 |
2012-11-08 |
Biogen Ma Inc. |
Treatment of conditions involving demyelination
|
ES2550099T3
(es)
|
2006-01-27 |
2015-11-04 |
Biogen Ma Inc. |
Antagonistas del receptor Nogo
|
KR20090010194A
(ko)
|
2006-04-13 |
2009-01-29 |
노바티스 백신즈 앤드 다이아그노스틱스, 인크. |
암의 치료, 진단 또는 검출 방법
|
NZ572561A
(en)
|
2006-06-07 |
2012-05-25 |
Bioalliance Cv |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
EA021255B1
(ru)
|
2006-08-28 |
2015-05-29 |
Киова Хакко Кирин Ко., Лимитед |
Антагонистические моноклональные антитела человека, специфичные в отношении light человека
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
JP5386364B2
(ja)
|
2006-12-18 |
2014-01-15 |
ジェネンテック, インコーポレイテッド |
抗Notch3アンタゴニスト抗体とNotch3関連疾患の予防及び治療におけるその使用
|
SI2099826T1
(sl)
|
2007-01-05 |
2014-02-28 |
University Of Zurich Prorektorat Forschung |
Anti-beta-amiloidno protitelo in njegova uporaba
|
EA036660B1
(ru)
|
2007-01-09 |
2020-12-04 |
Байоджен Эмэй Инк. |
АНТИТЕЛО К Sp35 ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
EA017403B1
(ru)
|
2007-02-02 |
2012-12-28 |
Байоджен Айдек Эмэй Инк. |
Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
|
EP2125898B1
(en)
|
2007-03-14 |
2013-05-15 |
Novartis AG |
Apcdd1 inhibitors for treating, diagnosing or detecting cancer
|
EP2599791A1
(en)
|
2007-04-27 |
2013-06-05 |
Genentech, Inc. |
Potent, stable and non-immunosuppressive anti-CD4 antibodies
|
RU2571515C2
(ru)
|
2007-08-29 |
2015-12-20 |
Санофи-Авентис |
Гуманизированные антитела к cxcr5, их производные и их применение
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
US8236316B2
(en)
|
2007-11-21 |
2012-08-07 |
Oregon Health & Science University |
Anti-factor XI monoclonal antibodies and methods of use thereof
|
KR101672271B1
(ko)
|
2007-12-18 |
2016-11-03 |
바이오얼라이언스 씨.브이. |
암세포에서 발현된 cd-43 및 cea 상의 탄수화물 함유 에피토프를 인식하는 항체 및 그것의 사용 방법
|
CN101932333A
(zh)
|
2007-12-26 |
2010-12-29 |
瓦西尼斯公司 |
抗c35抗体联合疗法和方法
|
WO2009118300A1
(en)
|
2008-03-25 |
2009-10-01 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
BRPI0911249A2
(pt)
|
2008-04-16 |
2017-05-23 |
Biogen Idec Inc |
método de isolamento de biomacromoléculas usando polialquileno glicol e metais de transição
|
AU2009269099B2
(en)
|
2008-07-09 |
2016-03-10 |
Biogen Ma Inc. |
Compositions comprising antibodies to LINGO or fragments thereof
|
RU2478648C2
(ru)
|
2008-09-07 |
2013-04-10 |
Гликонекс Инк. |
Антитело против удлиненного гликосфинголипида i типа, его производные и применение
|
JP2012507299A
(ja)
|
2008-10-31 |
2012-03-29 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Light標的分子およびその使用
|
DK2949666T3
(en)
|
2008-12-19 |
2019-03-25 |
Biogen Int Neuroscience Gmbh |
HUMAN ANTI-ALPHA SYNUCLEIN ANTIBODIES
|
JP2012514458A
(ja)
|
2008-12-31 |
2012-06-28 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
抗リンホトキシン抗体
|
EP2405920A1
(en)
|
2009-03-06 |
2012-01-18 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
CN102428103B
(zh)
|
2009-03-24 |
2015-04-08 |
泰华生物制药美国公司 |
抗light的人源化抗体及其使用
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
BRPI1016204A2
(pt)
|
2009-04-22 |
2016-04-19 |
Merck Patent Gmbh |
proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
|
US8496938B2
(en)
|
2009-05-08 |
2013-07-30 |
Vaccinex, Inc. |
Anti-CD100 neutralizing neutralizing antibodies and methods of using the same
|
SG178335A1
(en)
|
2009-08-13 |
2012-03-29 |
Crucell Holland Bv |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
EP2480573A1
(en)
|
2009-09-22 |
2012-08-01 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
JP6007420B2
(ja)
|
2009-11-04 |
2016-10-12 |
ファブラス エルエルシー |
親和性成熟に基づく抗体最適化方法
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
EP2561076A1
(en)
|
2010-04-19 |
2013-02-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
WO2011154485A1
(en)
|
2010-06-10 |
2011-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
SG10201800717UA
(en)
|
2010-07-09 |
2018-02-27 |
Janssen Vaccines & Prevention Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
US9034333B2
(en)
|
2010-08-27 |
2015-05-19 |
University Of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
JP6097690B2
(ja)
|
2010-09-02 |
2017-03-15 |
ヴァクシネックス, インコーポレイテッド |
抗cxcl13抗体およびそれを用いる方法
|
EP2614080A1
(en)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
NZ609984A
(en)
|
2010-10-11 |
2015-05-29 |
Biogen Idec Internat Neuroscience Gmbh |
Human anti-tau antibodies
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
CN103380145B
(zh)
|
2010-12-17 |
2016-10-12 |
生物控股有限公司 |
人类抗-sod1抗体
|
EP2686014A1
(en)
|
2011-03-16 |
2014-01-22 |
Sanofi |
Uses of a dual v region antibody-like protein
|
US9181553B2
(en)
|
2011-06-06 |
2015-11-10 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Method of treatment of breast cancers over-expressing the SHP2 signature genes
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
DK2723379T3
(en)
|
2011-06-23 |
2018-10-15 |
Biogen Int Neuroscience Gmbh |
ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
|
US20140234903A1
(en)
|
2011-09-05 |
2014-08-21 |
Eth Zurich |
Biosynthetic gene cluster for the production of peptide/protein analogues
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
US9221907B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Anti-GPR49 monoclonal antibodies
|
AU2012332587B2
(en)
|
2011-11-01 |
2017-02-23 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
EP2776838A1
(en)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
EP2776022A1
(en)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
TWI591074B
(zh)
|
2011-12-05 |
2017-07-11 |
X 染色體有限公司 |
PDGF受體β結合多肽
|
US20140363448A1
(en)
|
2012-01-02 |
2014-12-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
NZ629828A
(en)
|
2012-03-02 |
2017-05-26 |
Vaccinex Inc |
Methods for the treatment of b cell-mediated inflammatory diseases
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
DK2831113T3
(en)
|
2012-03-28 |
2018-06-25 |
Sanofi Sa |
ANTIBODIES AGAINST BRADYKININ-B1 RECEPTOR LIGANDS
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
WO2013169657A1
(en)
|
2012-05-07 |
2013-11-14 |
Sanofi |
Methods for preventing biofilm formation
|
NZ702178A
(en)
|
2012-05-14 |
2017-01-27 |
Biogen Ma Inc |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
MX369626B
(es)
|
2012-05-24 |
2019-11-13 |
Mountgate Group Ltd |
Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.
|
US20150218238A1
(en)
|
2012-06-29 |
2015-08-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Treating diseases by modulating a specific isoform of mkl1
|
EP2870242A1
(en)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
US20150224190A1
(en)
|
2012-07-06 |
2015-08-13 |
Mohamed Bentires-Alj |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
|
MY181648A
(en)
|
2012-08-24 |
2020-12-30 |
Univ California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
JP6284548B2
(ja)
|
2012-12-21 |
2018-02-28 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
ヒト抗タウ抗体
|
CA2896824A1
(en)
|
2012-12-31 |
2014-07-03 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
WO2014137355A1
(en)
|
2013-03-08 |
2014-09-12 |
Vaccinex, Inc. |
Anti-cxcl13 antibodies and associated epitope sequences
|
AU2014233198B2
(en)
|
2013-03-15 |
2019-06-27 |
Sutter West Bay Hospitals |
Falz for use as a target for therapies to treat cancer
|
NZ714765A
(en)
|
2013-06-06 |
2021-12-24 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
US20160178610A1
(en)
|
2013-08-07 |
2016-06-23 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment Friedreich's ataxia
|
JP6696899B2
(ja)
|
2013-08-13 |
2020-05-20 |
サノフイSanofi |
プラスミノーゲン活性化因子阻害剤−1(pai−1)に対する抗体及びその使用
|
TWI592426B
(zh)
|
2013-08-13 |
2017-07-21 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
SG11201603206UA
(en)
|
2013-10-24 |
2016-05-30 |
Medimmune Llc |
Stable, aqueous antibody formulations
|
JP6870988B2
(ja)
|
2014-02-24 |
2021-05-19 |
セルジーン コーポレイション |
神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015231155B2
(en)
|
2014-03-21 |
2020-11-12 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
US9546214B2
(en)
|
2014-04-04 |
2017-01-17 |
Bionomics, Inc. |
Humanized antibodies that bind LGR5
|
US20170137824A1
(en)
|
2014-06-13 |
2017-05-18 |
Indranil BANERJEE |
New treatment against influenza virus
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
WO2016001830A1
(en)
|
2014-07-01 |
2016-01-07 |
Friedrich Miescher Institute For Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
EP3197557A1
(en)
|
2014-09-24 |
2017-08-02 |
Friedrich Miescher Institute for Biomedical Research |
Lats and breast cancer
|
US10392447B2
(en)
|
2014-09-30 |
2019-08-27 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (DPRs) antibody
|
BR112017008383A2
(pt)
|
2014-10-31 |
2018-07-31 |
Medimmune Llc |
método de produção melhorado
|
CA2970352A1
(en)
|
2014-12-11 |
2016-06-16 |
Pierre Fabre Medicament |
Anti-c10orf54 antibodies and uses thereof
|
EP3242893A1
(en)
|
2015-01-08 |
2017-11-15 |
Biogen MA Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
FI3265123T3
(fi)
|
2015-03-03 |
2023-01-31 |
|
Vasta-aineita, käyttöjä & menetelmiä
|
JP6862351B2
(ja)
|
2015-03-31 |
2021-04-21 |
メドイミューン・リミテッドMedImmune Limited |
新規il33型、変異型のil33、抗体、アッセイ及びそれらの使用方法
|
JP7020687B2
(ja)
|
2015-09-15 |
2022-02-16 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
T細胞受容体(tcr)結合抗体及びその使用
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
US10472422B2
(en)
|
2016-01-08 |
2019-11-12 |
Abgenomics International Inc. |
Tetravalent anti-PSGL-1 antibodies and uses thereof
|
CA3017197A1
(en)
|
2016-03-10 |
2017-09-14 |
Viela Bio, Inc. |
Ilt7 binding molecules and methods of using the same
|
CN108697799A
(zh)
|
2016-03-22 |
2018-10-23 |
生态学有限公司 |
抗lgr5单克隆抗体的施用
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
EP3618865A4
(en)
|
2017-05-05 |
2021-05-05 |
Vaccinex, Inc. |
4D ANTI-SEMAPHORIN HUMAN ANTIBODY
|
CN111587123A
(zh)
|
2017-11-09 |
2020-08-25 |
品通治疗有限公司 |
用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
|
CA3083345A1
(en)
|
2017-11-27 |
2019-05-31 |
Purdue Pharma L.P. |
Humanized antibodies targeting human tissue factor
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
AU2020221821A1
(en)
|
2019-02-13 |
2021-08-26 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
WO2020206063A1
(en)
|
2019-04-03 |
2020-10-08 |
Genzyme Corporation |
Anti-alpha beta tcr binding polypeptides with reduced fragmentation
|
EP3976181A1
(en)
|
2019-05-24 |
2022-04-06 |
Sanofi |
Methods for treating systemic sclerosis
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
CN117425501A
(zh)
|
2021-01-13 |
2024-01-19 |
纪念斯隆凯特琳癌症中心 |
抗体-吡咯并苯二氮䓬衍生物缀合物
|
WO2022153195A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|